Aarti Drugs Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Aarti Drugs Ltd is ₹ 398.3 as of 06 May 15:30 . The P/E Ratio of Aarti Drugs Ltd changed from 23.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of -4.34% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Aarti Drugs Ltd changed from ₹ 6475 crore on March 2021 to ₹ 3123 crore on March 2025 . This represents a CAGR of -13.57% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Aarti Drugs Ltd for the Dec '25 is ₹ 602.94 crore as compare to the Sep '25 revenue of ₹ 652.88 crore. This represent the decline of -7.65% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Aarti Drugs Ltd for the Dec '25 is ₹ 56.26 crore as compare to the Sep '25 ebitda of ₹ 84.37 crore. This represent the decline of -33.32% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Aarti Drugs Ltd changed from ₹ 33.27 crore to ₹ 40.55 crore over 7 quarters. This represents a CAGR of 11.97% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Aarti Drugs Ltd changed from 9.04 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -8.49% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Aarti Drugs Ltd

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Aarti Drugs Ltd is 3,635 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 6, 2026, the Aarti Drugs Ltd stock price is INR ₹398.3. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3.

How do dividend payouts of Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.